Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30031976 | 0.88 | LMNA (0.60) | HSP90AA1SMN1; SMN2TSHRKMT2AMEN1 | |
| SCHEMBL1448439 | 0.88 | LMNA (0.60) | HSP90AA1SMN1; SMN2TSHRKMT2AMEN1 | |
| SCHEMBL3342742 | 0.86 | HPGD (0.51) | HSP90AA1SMN1; SMN2TSHRKMT2AMEN1 | |
| SCHEMBL30033208 | 0.86 | HPGD (0.55) | HSP90AA1SMN1; SMN2TSHRKMT2AMEN1 | |
| SCHEMBL2106649 | 0.86 | HPGD (0.55) | HSP90AA1SMN1; SMN2TSHRKMT2AMEN1 | |
| SCHEMBL30032014 | 0.84 | HPGD (0.58) | HSP90AA1SMN1; SMN2TSHRKMT2AMEN1 | |
| SCHEMBL1447592 | 0.83 | KMT2A (0.67) | HSP90AA1TSHRKMT2AMEN1LMNA | |
| SCHEMBL30033450 | 0.82 | MAPT (0.61) | HSP90AA1SMN1; SMN2TSHRKMT2AHPGD | |
| SCHEMBL1447959 | 0.82 | MAPT (0.61) | HSP90AA1SMN1; SMN2TSHRKMT2AHPGD | |
| SCHEMBL30032106 | 0.81 | POLB (0.56) | KMT2AMEN1LMNAMAPK1GFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220363662-A1 | COMPOUNDS AS LXR AGONISTS | Integral Biosciences Privated Limited (IN) | 2022-11-17 | — | — | US | disclosed |
| WO-2022224166-A1 | COMPOUNDS AS LXR AGONISTS | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2022-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363662-A1 | COMPOUNDS AS LXR AGONISTS | NR1H2, NR1H3, NR1H4 | HSP90AA1 3568/4885SMN1; SMN2 4094/4885TSHR 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.